Searched for
CADILA HEALTH
Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 29%In the current phase of market volatility, the only solace to be derived is from market history. And history tells us that, just like good ...- Zydus Cadila gets US health regulator nod for multiple sclerosis treatment drugZydus Cadila has received final approval from the United States Food and Drug Administration (USFDA) to market Dimethyl Fumarate delayed re...
- Zydus Cadila gets USFDA nod for breast cancer drugThe company said it will manufacture the drug at the group's formulations manufacturing facility at SEZ, Ahmedabad.
- Cadila up 2% as Gujarat plant gets no USFDA observationThe company had recently reported 53.26 per cent jump in consolidated net profit at Rs 590.8 crore.
- Zydus starts phase II trials of molecule targeting anaemiaAnaemia commonly arises in kidney disease patients, because the kidneys no longer produce sufficient amounts of erythropoietin, a hormone w...
- Zydus Cadila gets USFDA nod for ezetimibe tabletsThe group now has around 115 approvals from USFDA and has so far filed 300 abbreviated new drug applications (ANDAs), the company said.
- Pankaj Patel owned Cadila ups its India game with AZ’s brandsAs part of the agreement, AZ will sell the following brands of Bricarex, Bricarex-A, Bricanyl, Xylocard, Ceriviprime, Prostodin, Partocin a...
- Sell Cadila Health with a target of Rs 390: Mitesh Thacker"Cadila Health is a 'SELL' call with a target of Rs 390 and a stop loss of Rs 413."
- Zydus gets USFDA tentative nod to market anti-diabetic tablets"The group now has 97 approvals and has so far filed 249 ANDAs since the commencement of the filing process in 2003-2004."
- Cadila Health is a buy call with a target of Rs 1100: Mitesh ThackerCadila Health is a 'BUY' call with a target of Rs 1100 and a stop loss of Rs 1024.
- Cadila Health, Torrent Pharma mulling merger: SourcesIf talks succeed, the new entity will become India's third largest pharma co in terms of sales going forward after Sun Pharmaceuticals & Dr...
- Zydus Cadila gets USFDFA nod to market anti-ulcer capsulesThe product had estimated sales of $501 million in 2012 as per the IMS Health data, it added.
- Pharma stocks surge up to 5.5% on value-buyingPharma stocks led by Apollo Hospitals, Cadila Health and Dr Reddy's Lab today gained as much as 5.5 per cent on value-buying in an otherwis...
- Zydus Cadila Group to merge its three subsidiaries with its listed entity Cadila Healthcare LtdIn 2000, Zydus Cadila had created a strategic alliance with Ambalal Sarabhai Enterprises to integrate the animal healthcare business of bot...
- Cadila Healthcare to merge certain subsidiaries with itselfDrug maker Cadila Healthcare today said its board has approved the merger of various wholly-owned subsidiaries, including Zydus Animal Heal...
- Stock Buzz: Persistent Systems, Cadila top investment ideasInvestors should align themselves with businesses which are export oriented, and with companies which will benefit if rupee depreciates.
- Cadila Health Q3 net dips 31% at Rs 102.91 croreCadila Healthcare today reported 31.03 per cent dip in consolidated net profit to Rs 102.91 crore for its third quarter ended December 31.
- Cadila launches Parkinson's generic drug in the US marketCadila Healthcare said it has launched generic Pramipexole tablets, used for treating Parkinson's disease, in the US market.
- Cadila drags Dabur to HC for use of its trademark 'Sugar Free'Pharma major Cadila Health care, a market leader in sugar substitute business, has dragged Dabur India for use of its 'Sugar Free' trademar...
- Cadila drags Dabur to HC for use of its trademark 'Sugar Free'Pharma major Cadila Health care, a market leader in sugar substitute business, has dragged Dabur India for use of its 'Sugar Free' trademar...
Load More
